Fulvestrant is a novel hormone receptor antagonist that causes rapid degradation of both the ER and the progesterone receptor (PgR) [36] and has been shown to be highly effective for treating late stage breast cancer [37]. This evidence concerns the gene NR4A1 and breast carcinoma.